← Leaderboards
Julie Brumer Dumond
Univ Of North Carolina Chapel Hill
$5,578,599
Attributed
$5,578,599
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $939.7K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,578,599 · 6
By mechanism
R01$3,668,790 · 2
R21$797,516 · 2
R56$567,218 · 1
K23$545,075 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Ronald I Swanstrom$43,560,887
- Toni Darville$28,754,279
- Daniel Gonzalez$6,378,664
- Carla J Chibwesha$4,372,568
- Ian J Davis$7,130,869
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingPharmaceutical PreparationsProspectiveAgingAnti-Retroviral AgentsTenofovirPeripheral Blood Mononuclear CellPlasmaDrug KineticsRegimenToxic EffectPharmacokinetic ModelAntiretroviral TherapyFrailtyAffectCohortAdultImmunologicsClinical TrialsClinical PharmacologyAge RelatedCellsOlder PatientInterest
Grant awards (16)
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study$579,148
R01 · FY2025 · AI · contact PI
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study$621,756
R01 · FY2024 · AI · contact PI
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study$744,135
R01 · FY2023 · AI · contact PI
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study$724,842
R01 · FY2022 · AI · contact PI
Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity$214,861
R01 · FY2022 · HD · contact PI
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study$784,048
R01 · FY2021 · AI · contact PI
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study$567,218
R56 · FY2020 · AI · contact PI
Interaction of Nucleoside Reverse Transcriptase Inhibitor Pharmacology and Aging in the Multicenter AIDS Cohort Study$230,075
R21 · FY2020 · AG · contact PI
Interaction of Nucleoside Reverse Transcriptase Inhibitor Pharmacology and Aging in the Multicenter AIDS Cohort Study$193,450
R21 · FY2019 · AG · contact PI
Effects of Aging and Inflammation on Intracellular Nucleoside Reverse Transcriptase Inhibitor Pharmacology in the WIHS Cohort$136,703
R21 · FY2019 · AG · contact PI
Effects of Aging and Inflammation on Intracellular Nucleoside Reverse Transcriptase Inhibitor Pharmacology in the WIHS Cohort$237,288
R21 · FY2018 · AG · contact PI
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity$109,239
K23 · FY2015 · AI · contact PI
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity$109,239
K23 · FY2014 · AI · contact PI
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity$109,239
K23 · FY2013 · AI · contact PI
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity$109,239
K23 · FY2012 · AI · contact PI
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity$108,119
K23 · FY2011 · AI · contact PI